CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris
Launched by CELTAXSYS, INC. · Mar 5, 2015
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Must provide Informed consent.
- • 2. Male or female aged 16 to 44 inclusive.
- • 3. Moderate to severe facial acne vulgaris as defined in the protocol.
- Exclusion Criteria:
- • 1. Positive testing for HIV, HBsAg, or hepatitis C virus (HCV).
- • 2. Females who are pregnant, lactating, or planning to become pregnant during the study.
- • 3. Any systemic medical condition which, in the opinion of the investigator, would put the participant at risk by participation in the study.
- • 4. Any systemic or dermatologic disorder that, in the opinion of the investigator will interfere with the assessment of the study endpoints (e.g. psoriasis).
- • 5. Concurrent or previous use of an investigational drug or device within 30 days prior to screening.
- • 6. The presence of acne conglobata, acne fulminans, secondary acne, or nodulocystic acne.
- • 7. The presence of known or suspicious unresolved dermatological cancerous or pre-cancerous lesions.
- • 8. Hypersensitivity or idiosyncratic reaction to compounds related to CTX-4430 or any of its components.
About Celtaxsys, Inc.
Celtaxsys, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs, particularly in the field of inflammation and autoimmune disorders. With a commitment to advancing scientific research and improving patient outcomes, Celtaxsys leverages its proprietary technology platform to identify and develop novel compounds that address the underlying mechanisms of disease. The company aims to translate its discoveries into effective treatments, collaborating with leading researchers and healthcare professionals to enhance the quality of care for individuals suffering from chronic inflammatory conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brisbane, Queensland, Australia
Fremantle, Western Australia, Australia
Benowa, Queensland, Australia
Carlton, Victoria, Australia
Kogarah, New South Wales, Australia
Auckland, , New Zealand
Sydney, New South Wales, Australia
Woolloongabba, Queensland, Australia
Phillip, Australian Capital Territory, Australia
Hamilton, , New Zealand
Patients applied
Trial Officials
Lynda J Spelman, MB BS, FACD
Principal Investigator
Veracity Clinical Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials